<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Disulfiram: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Disulfiram: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Disulfiram: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12390" href="/d/html/12390.html" rel="external">see "Disulfiram: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708705"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Alcohol intoxication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Disulfiram should never be administered to a patient when they are in a state of alcohol intoxication, or without their full knowledge. The physician should instruct relatives accordingly.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F161760"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Antabuse [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F161796"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Aldehyde Dehydrogenase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F161762"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9192803-8b96-41ab-8488-f36d16324eb4">Alcohol use disorder, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcohol use disorder, moderate to severe (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Suggested for use in patients who want to abstain from alcohol, have sufficient social support, and either prefer disulfiram or are unable to tolerate other preferred therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29301420','lexi-content-ref-Holt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29301420','lexi-content-ref-Holt.1'])">Ref</a></span>). Do not administer until the patient has abstained from alcohol for at least 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); some experts suggest waiting 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.1'])">Ref</a></span>). Patients should be advised that reactions with alcohol can occur up to 14 days after taking disulfiram (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29301420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29301420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 250 to 500 mg once daily for 1 to 2 weeks; afterward, may adjust based on response and tolerability to a maintenance range of 125 to 500 mg once daily; usual maintenance dose: 250 mg once daily; maximum dose: 500 mg/day. Some experts consider alternative therapy if goals are not met within 6 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5f370d68-4b41-4115-960b-9a4cc4d9af5b">Cocaine use disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cocaine use disorder (adjunctive therapy) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Used concomitantly with other substance use disorder treatments, including psychotherapy or methadone.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 250 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14993114','lexi-content-ref-22695473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14993114','lexi-content-ref-22695473'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990285"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with extreme caution in chronic and acute nephritis.</p></div>
<div class="block doha drugH1Div" id="F50987578"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with extreme caution in hepatic cirrhosis or insufficiency.</p></div>
<div class="block doe drugH1Div" id="F161763"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use with caution, starting at low end of dosing range.</p></div>
<div class="block adr drugH1Div" id="F161735"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic dermatitis (Fusta-Novell 2018), exfoliative dermatitis (Radaschin 2020), macular eruption (Radaschin 2020), pruritus (Radaschin 2020), skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (Ranek 1977)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (Ranek 1977), hepatitis (including cholestatic hepatitis and fulminant hepatitis) (Kahn 1990; Mohanty 2004), hepatotoxicity (Ranek 1977)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including acneiform eruption, erythema of skin, and exfoliation of skin) (Nassberger 1984)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal behavior (punding) (Fan 2008), bitter taste (garlic) (Kump 1979), catatonia (Reisberg 1978), delusion (Capgras syndrome) (Daniel 1987), drowsiness (Radaschin 2020), encephalopathy (organic brain syndrome) (Kump 1979; Reisberg 1978), fatigue (Radaschin 2020), headache (Radaschin 2020), manic behavior (with psychosis) (Li 2008), metallic taste (Kump 1979; Radaschin 2020), neuropathy (including axonal peripheral polyneuropathy, peripheral neuropathy, polyneuropathy, and sensorimotor neuropathy) (Coronel 2022; Tran 2016; Watson 1980), psychotic reaction (including delirium) (Rossiter 1992), seizure (Daniel 1987)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis (Leibold 1971)</p></div>
<div class="block coi drugH1Div" id="F161748"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to disulfiram or any component of the formulation or to other thiuram derivatives used in pesticides and rubber vulcanization; patients receiving or using alcohol, metronidazole, paraldehyde, or alcohol-containing preparations (eg, cough syrup, tonics); psychosis; severe myocardial disease or coronary occlusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F161732"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Disulfiram reaction: Ingesting alcohol, even in small amounts, during treatment with disulfiram may result in flushing, throbbing in head and neck, nausea, copious vomiting, respiratory difficulty, diaphoresis, thirst, chest pain, palpitation, dyspnea, hyperventilation, tachycardia, hypotension, syncope, marked uneasiness, weakness, vertigo, blurred vision and confusion. Severe reactions may involve respiratory depression, cardiovascular collapse, arrhythmias, myocardial infarction, acute congestive heart failure, unconsciousness, seizure and death. The intensity of the reaction is generally proportional to the amounts of disulfiram and alcohol ingested. The reaction can last from 30 minutes to several hours in more severe cases, or as long as it takes the alcohol to be metabolized. Patients should avoid alcohol consumption for ≥12 hours prior to administration (manufacturer’s labeling); some experts suggest waiting 48 hours (Holt 2022). Disulfiram reactions can occur up to 14 days after taking disulfiram if alcohol is consumed (APA [Reus 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Severe (sometimes fatal) hepatitis and/or hepatic failure resulting in transplantation have been associated with use; may occur in patients with or without prior history of abnormal hepatic function. Monitor for hepatotoxicity and educate patients about signs and symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebral damage: Use with extreme caution in patients with cerebral damage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Contact dermatitis: Evaluate patients with a history of rubber contact dermatitis for hypersensitivity to thiuram derivatives before administering disulfiram.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with extreme caution in patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with extreme caution in patients with hepatic cirrhosis or impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypothyroidism: Use with extreme caution in patients with hypothyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephritis: Use with extreme caution in patients with acute or chronic nephritis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with extreme caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alcohol intoxication: <b>[US Boxed Warning]: Should never be administered to a patient when they are in a state of alcohol intoxication, or without their full knowledge. The physician should instruct relatives accordingly.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patient information: Patients must receive appropriate counseling, including information on the disulfiram reaction, “disguised” forms of alcohol (eg, tonics, mouthwashes, cough mixtures, sauces, vinegars, aftershave lotions, back rubs) and the duration of drug activity (up to 14 days).</p></div>
<div class="block foc drugH1Div" id="F161742"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antabuse: 250 mg [DSC], 500 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F161728"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F161750"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Disulfiram Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $3.40 - $11.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $16.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F161745"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administration of any medications containing alcohol (eg, elixirs), including topicals, is contraindicated. Do not administer disulfiram if alcohol has been consumed within the prior 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); some experts suggest waiting 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.1'])">Ref</a></span>). Morning administration is preferred but may be given at bedtime if sedation is experienced. Tablets may be crushed and mixed with liquids.</p></div>
<div class="block use drugH1Div" id="F161743"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Alcohol use disorder, moderate to severe:</b> Management of chronic alcohol use disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Generally not first-line for alcohol use disorder due to tolerability issues; suggested for use in patients with alcohol use disorder (moderate to severe) who want to abstain from alcohol and either prefer disulfiram or are unable to tolerate or are unresponsive to naltrexone and acamprosate (APA [Reus 2018]).</p></div>
<div class="block off-label drugH1Div" id="F56031818"><span class="drugH1">Use: Off-Label: Adult</span><p>Cocaine use disorder</p></div>
<div class="block mst drugH1Div" id="F161803"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Disulfiram may be confused with Diflucan</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F161792"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak), CYP2E1 (strong)</p></div>
<div class="block dri drugH1Div" id="F161737"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): Disulfiram may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May diminish the therapeutic effect of Disulfiram.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacampicillin: May enhance the adverse/toxic effect of Disulfiram.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benznidazole: May enhance the adverse/toxic effect of Disulfiram. In particular, the risk for CNS toxicities such as psychosis may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlordiazePOXIDE: Disulfiram may increase the serum concentration of ChlordiazePOXIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorzoxazone: CYP2E1 Inhibitors (Strong) may increase the serum concentration of Chlorzoxazone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): Disulfiram may increase the serum concentration of Cocaine (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: Disulfiram may enhance the adverse/toxic effect of DroNABinol. Specifically, disulfiram may produce severe intolerance to the alcohol contained in the dronabinol oral solution. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the adverse/toxic effect of Disulfiram.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: Disulfiram may increase the serum concentration of Flunitrazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Disulfiram may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ilaprazole: May increase the serum concentration of Disulfiram.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: CYP2E1 Inhibitors (Strong) may increase the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kombucha: Disulfiram may enhance the adverse/toxic effect of Kombucha. A disulfiram-like reaction may occur. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): Disulfiram may enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). In particular, the risk for CNS toxicities such as psychosis may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Topical): May enhance the adverse/toxic effect of Disulfiram. In particular, the risk for CNS toxicities such as psychosis may be increased. Management: Warn patients and monitor for the development of serious CNS toxicity if topical metronidazole is used in a patient taking disulfiram. Some manufacturers of vaginal metronidazole products list disulfiram use within 2 weeks as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: Disulfiram may increase the serum concentration of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Products Containing Ethanol: Disulfiram may enhance the adverse/toxic effect of Products Containing Ethanol.  Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline: Disulfiram may increase the serum concentration of Theophylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tinidazole: May enhance the adverse/toxic effect of Disulfiram.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: Disulfiram may enhance the adverse/toxic effect of Tipranavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Disulfiram may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F161757"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Disulfiram inhibits the usual metabolism of alcohol. Patients can have a disulfiram reaction (headache, nausea, vomiting, chest, or abdominal pain) if they drink alcohol concurrently. Management: Avoid all alcohol for at least 12 hours before taking a dose (manufacturer’s labeling); some experts suggest waiting 48 hours (Holt 2022). Disulfiram reactions can occur up to 14 days after taking disulfiram if alcohol is consumed (APA [Reus 2018]). Avoid cough syrups and elixirs containing alcohol. Avoid vinegars, cider, extracts, and foods containing alcohol.</p></div>
<div class="block pri drugH1Div" id="F21099943"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Safety in pregnancy has not been established; there is limited data on maternal use during pregnancy (Reitnauer 1997).</p>
<p style="text-indent:0em;margin-top:2em;">Pharmacological agents should not be used for the treatment of alcohol use disorder in pregnant women unless needed for the treatment of acute alcohol withdrawal or a coexisting disorder; agents other than disulfiram are recommended for acute alcohol withdrawal.</p></div>
<div class="block brc drugH1Div" id="F20305983"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if disulfiram is present in breast milk. Breastfeeding is not recommended by the manufacturer. Pharmacological agents should not be used for the treatment of alcohol use disorder in breastfeeding women unless needed for the treatment of acute alcohol withdrawal or a coexisting disorder; agents other than disulfiram are recommended for acute alcohol withdrawal (APA [Reus 2018]).</p></div>
<div class="block dic drugH1Div" id="F9497261"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Do not administer disulfiram if alcohol has been consumed within the prior 12 hours (manufacturer’s labeling); some experts suggest waiting 48 hours (Holt 2022).</p></div>
<div class="block mop drugH1Div" id="F161740"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver function tests (baseline and after 10 to 14 days of treatment), CBC, serum chemistries; cardiac function at baseline if clinically appropriate (APA [Reus 2018])</p></div>
<div class="block pha drugH1Div" id="F161731"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Disulfiram is a thiuram derivative which blocks the oxidation of alcohol at the acetaldehyde stage. When taken concomitantly with alcohol, there is an increase in serum acetaldehyde levels. High acetaldehyde causes uncomfortable symptoms including flushing, throbbing in head and neck, nausea, vomiting, diaphoresis, thirst, palpitations, chest pain, dyspnea, hyperventilation, tachycardia, syncope, weakness, blurred vision, confusion, vertigo, and hypotension. This reaction is the basis for disulfiram use in post-withdrawal long-term care of alcohol use disorder.</p></div>
<div class="block phk drugH1Div" id="F161747"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Full effect: 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: ~1 to 2 weeks after last dose</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Slow</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Reduction of disulfide linkage to diethyldithiocarbamic acid, then further metabolized via glucuronidation, non-enzymatic degradation, methylation and oxidation (Eneanya 1981)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (20% unchanged) and exhaled gases (as metabolites), urine (50% metabolites) (Eneanya 1981)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F161751"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Abstensyl | Disulfix | Vandisul</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Antabus</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Antabuse</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Antabuse | Esperal</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Anticol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Antietanol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Antabus</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Antabus | Tolerane</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Antabus | Esperal</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Antabus dispergett</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Antabus</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Antaethyl | Anticol | Esperal</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Antabus</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Esperal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Antabuse</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Antaethyl</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Antabuse</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Antabuse</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alcoford | Alwid | Cronodol | D sulf | De quit | Deadict | Dizone | Esperal | Lifexone | Tyfusin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Antabuse</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Antabuse d</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alcohol stop</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Antabus | Anticol | Deaddict | Esperal | Lidevin | Teturam</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Antabuse</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Antabus | Anticol | Esperal | Teturam</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Etabus</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Antabus | Refusal</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Antabuse</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Busetal</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Antabus | Antalcol | Anticol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Antabuse</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Esperal | Tetradin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Antalcol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Esperal | Teturam</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Antabuse</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Antabus</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alcobute | Anta AL | Antabuse | Antinol | Chronol | Difiram | Rossee</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Antabus</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Antabus | Esperal</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Esperal | Teturam</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Antabuse</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Antabuse (disulfiram) [prescribing information]. North Wales, PA: Teva Pharmaceuticals; September 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14993114">
<a name="14993114"></a>Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. <i>Arch Gen Psychiatry</i>. 2004;61(3):264-272. doi:10.1001/archpsyc.61.3.264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/14993114/pubmed" id="14993114" target="_blank">14993114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9692270">
<a name="9692270"></a>Carroll KM, Nich C, Ball SA, McCance E, Rounsavile BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. <i>Addiction</i>. 1998;93(5):713-727. doi:10.1046/j.1360-0443.1998.9357137.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/9692270/pubmed" id="9692270" target="_blank">9692270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22695473">
<a name="22695473"></a>Carroll KM, Nich C, Shi JM, Eagan D, Ball SA. Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. <i>Drug Alcohol Depend</i>. 2012;126(1-2):224-231. doi:10.1016/j.drugalcdep.2012.05.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/22695473/pubmed" id="22695473" target="_blank">22695473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35608643">
<a name="35608643"></a>Coronel SI, Dorman J. Use of neuromuscular ultrasound in the diagnosis of disulfiram polyneuropathy. <i>J Clin Neuromuscul Dis</i>. 2022;23(4):201-204. doi:10.1097/CND.0000000000000380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/35608643/pubmed" id="35608643" target="_blank">35608643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3423903">
<a name="3423903"></a>Daniel DG, Swallows A, Wolff F. Capgras delusion and seizures in association with therapeutic dosages of disulfiram. <i>South Med J</i>. 1987;80(12):1577-1579. doi:10.1097/00007611-198712000-00022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/3423903/pubmed" id="3423903" target="_blank">3423903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sigmapharm.1">
<a name="Sigmapharm.1"></a>Disulfiram (tablets, USP) [prescribing information]. Bensalem, PA: Sigmapharm Laboratories LLC; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7016017">
<a name="7016017"></a>Eneanya DI, Bianchine JR, Duran DO, Andresen BD. The actions of metabolic fate of disulfiram. <i>Annu Rev Pharmacol Toxicol</i>. 1981;21:575-596.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/7016017/pubmed" id="7016017" target="_blank">7016017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18626287">
<a name="18626287"></a>Fan CC, Lin SK, Huang MC. Disulfiram-induced punding. <i>J Clin Psychopharmacol</i>. 2008;28(4):473-474. doi:10.1097/JCP.0b013e31817d8702<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/18626287/pubmed" id="18626287" target="_blank">18626287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29806205">
<a name="29806205"></a>Fustà-Novell X, Gómez-Armayones S, Morgado-Carrasco D, Mascaró JM Jr. Systemic allergic dermatitis caused by disulfiram (Antabuse) in a patient previously sensitized to rubber accelerators. <i>Contact Dermatitis</i>. 2018;79(4):239-240. doi:10.1111/cod.13030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/29806205/pubmed" id="29806205" target="_blank">29806205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holt.1">
<a name="Holt.1"></a>Holt SR. Alcohol use disorder: pharmacologic management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2196696">
<a name="2196696"></a>Kahn S, Farnum JB, Thomas E. Disulfiram-induced hepatitis. <i>South Med J</i>. 1990;83(7):833-836. doi:10.1097/00007611-199007000-00026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/2196696/pubmed" id="2196696" target="_blank">2196696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-472804">
<a name="472804"></a>Kump JG, Flaten PA, Greenlaw CW. Disulfiram-induced acute organic brain syndrome. <i>South Med J</i>. 1979;72(8):1023-1024. doi:10.1097/00007611-197908000-00042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/472804/pubmed" id="472804" target="_blank">472804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4338111">
<a name="4338111"></a>Leibold JE. Drugs having a toxic effect on the optic nerve. <i>Int Ophthalmol Clin</i>. 1971;11(2):137-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/4338111/pubmed" id="4338111" target="_blank">4338111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17904262">
<a name="17904262"></a>Li MY, Shen YC. Manic episode with psychosis following a lower than recommended dosage regimen of disulfiram. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2008;32(1):311-312. doi:10.1016/j.pnpbp.2007.08.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/17904262/pubmed" id="17904262" target="_blank">17904262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15128079">
<a name="15128079"></a>Mohanty SR, LaBrecque DR, Mitros FA, Layden TJ. Liver transplantation for disulfiram-induced fulminant hepatic failure. <i>J Clin Gastroenterol</i>. 2004;38(3):292-295. doi:10.1097/00004836-200403000-00018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/15128079/pubmed" id="15128079" target="_blank">15128079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6483711">
<a name="6483711"></a>Nässberger L. Disulfiram-induced hepatitis--report of a case and review of the literature. <i>Postgrad Med J</i>. 1984;60(707):639-641. doi:10.1136/pgmj.60.707.639<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/6483711/pubmed" id="6483711" target="_blank">6483711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10723850">
<a name="10723850"></a>Petrakis IL, Carroll KM, Nich C, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. <i>Addiction</i>. 2000;95(2):219-228. doi:10.1046/j.1360-0443.2000.9522198.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/10723850/pubmed" id="10723850" target="_blank">10723850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33416246">
<a name="33416246"></a>Radaschin DS, Bujoreanu FC, Tatu AL. Disulfiram-induced baboon Syndrome. <i>Am J Ther</i>. 2020;29(2):e272-e273. doi:10.1097/MJT.0000000000001227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/33416246/pubmed" id="33416246" target="_blank">33416246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-871808">
<a name="871808"></a>Ranek L, Buch Andreasen P. Disulfiram hepatotoxicity. <i>Br Med J</i>. 1977;2(6079):94-96. doi:10.1136/bmj.2.6079.94<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/871808/pubmed" id="871808" target="_blank">871808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-681921">
<a name="681921"></a>Reisberg B. Catatonia associated with disulfiram therapy. <i>J Nerv Ment Dis</i>. 1978;166(8):607-609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/681921/pubmed" id="681921" target="_blank">681921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9485545">
<a name="9485545"></a>Reitnauer PJ, Callanan NP, Farber RA, Aylsworth AS. Prenatal exposure to disulfiram implicated in the cause of malformations in discordant monozygotic twins. <i>Teratology</i>. 1997;56(6):358-362. DOI: 10.1002/(SICI)1096-9926(199712)56:6&lt;358::AID-TERA3&gt;3.0.CO;2-S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/9485545/pubmed" id="9485545" target="_blank">9485545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29301420">
<a name="29301420"></a>Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder.<i> Am J Psychiatry</i>. 2018;175(1):86-90. doi: 10.1176/appi.ajp.2017.1750101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/29301420/pubmed" id="29301420" target="_blank">29301420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1422334">
<a name="1422334"></a>Rossiter SK. Psychosis with disulfiram prescribed under probation order. <i>BMJ</i>. 1992;305(6856):763. doi:10.1136/bmj.305.6856.763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/1422334/pubmed" id="1422334" target="_blank">1422334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27029711">
<a name="27029711"></a>Tran AT, Rison RA, Beydoun SR. Disulfiram neuropathy: two case reports. <i>J Med Case Rep</i>. 2016;10:72. doi:10.1186/s13256-016-0865-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/27029711/pubmed" id="27029711" target="_blank">27029711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6266628">
<a name="6266628"></a>Watson CP, Ashby P, Bilbao JM. Disulfiram neuropathy. <i>Can Med Assoc J</i>. 1980;123(2):123-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/disulfiram-drug-information/abstract-text/6266628/pubmed" id="6266628" target="_blank">6266628</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9379 Version 239.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
